Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P35968
UPID:
VGFR2_HUMAN
Alternative names:
Fetal liver kinase 1; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1
Alternative UPACC:
P35968; A2RRS0; B5A925; C5IFA0; O60723; Q14178
Background:
Vascular endothelial growth factor receptor 2 (VEGFR-2), also known as Kinase insert domain receptor (KDR), plays a pivotal role in vascular development and angiogenesis. It acts as a cell-surface receptor for VEGFA, VEGFC, and VEGFD, promoting endothelial cell proliferation, survival, migration, and differentiation. VEGFR-2 activation triggers multiple signaling pathways, including MAPK, AKT1, and PLCG1, essential for vascular permeability and embryonic hematopoiesis.
Therapeutic significance:
VEGFR-2 is linked to capillary infantile hemangioma, a condition marked by localized growth of capillary endothelium. Understanding VEGFR-2's role could lead to innovative treatments for angiogenesis-related diseases, offering hope for conditions characterized by abnormal blood vessel growth.